Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis
H Bantel, C Berg, M Vieth, M Stolte… - Official journal of the …, 2000 - journals.lww.com
H Bantel, C Berg, M Vieth, M Stolte, W Kruis, K Schulze-Osthoff
Official journal of the American College of Gastroenterology| ACG, 2000•journals.lww.comOBJECTIVES: The salicylate mesalazine is commonly used for the treatment of inflammatory
bowel diseases, yet its precise mechanism of action is unknown. Because transcription
factor NF-κB plays an important role in inflammatory bowel diseases, we investigated the
effects of mesalazine therapy on NF-κB activation in patients with ulcerative colitis.
METHODS: A total of 20 patients with moderately active ulcerative colitis received
mesalazine for 8 wk. Biopsies were taken before and after drug administration and analyzed …
bowel diseases, yet its precise mechanism of action is unknown. Because transcription
factor NF-κB plays an important role in inflammatory bowel diseases, we investigated the
effects of mesalazine therapy on NF-κB activation in patients with ulcerative colitis.
METHODS: A total of 20 patients with moderately active ulcerative colitis received
mesalazine for 8 wk. Biopsies were taken before and after drug administration and analyzed …
Abstract
OBJECTIVES:
The salicylate mesalazine is commonly used for the treatment of inflammatory bowel diseases, yet its precise mechanism of action is unknown. Because transcription factor NF-κB plays an important role in inflammatory bowel diseases, we investigated the effects of mesalazine therapy on NF-κB activation in patients with ulcerative colitis.
METHODS:
A total of 20 patients with moderately active ulcerative colitis received mesalazine for 8 wk. Biopsies were taken before and after drug administration and analyzed for NF-κB activation using an antibody specific for active NF-κB.
RESULTS:
In biopsies of active ulcerative colitis but not in noninflamed mucosa, activation of NF-κB was detected predominantly in macrophages. Mesalazine therapy resulted in a strong abrogation of NF-κB activation in situ.
CONCLUSIONS:
Our results suggest that the therapeutic properties of mesalazine rely at least in part on the inhibition of NF-κB activation, resulting in the suppression of proinflammatory gene expression in the inflamed mucosa.
Lippincott Williams & Wilkins